Cellectis has patented a method for adaptive cell immunotherapy involving genetic insertion of coding sequences into immune cells to enhance their response against infected or malignant cells. The engineered primary human NK or T cells secrete interleukins under endogenous gene promoters, improving therapeutic potential. GlobalData’s report on Cellectis gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Cellectis, CAR-T cell based therapies was a key innovation area identified from patents. Cellectis's grant share as of January 2024 was 36%. Grant share is based on the ratio of number of grants to total number of patents.
Genetic insertion in immune cells to target infected cells
A recently granted patent (Publication Number: US11873511B2) discloses a population of engineered primary human NK or T cells that have been modified to include an exogenous coding sequence encoding interleukins such as IL-15, IL-12, or IL-2. These interleukins are inserted into an endogenous gene, specifically PD1, under the control of the endogenous gene promoter locus. Additionally, these modified cells also contain a chimeric antigen receptor (CAR) or a recombinant TCR, with the engineered cells capable of secreting interleukins at levels that enhance their antitumor activity.
Furthermore, the patent claims specify various configurations and compositions of the engineered primary human NK or T cells, including the percentage of TCR negative T-cells and CAR positive cells, as well as the insertion of CARs at specific genetic loci using TALENS. The patent also details the insertion of interleukin coding sequences into the PD1 open reading frame using TALENS. These engineered cells represent a novel approach to enhancing the antitumor activity of primary human NK or T cells through genetic modifications that optimize the secretion of interleukins and the expression of CARs or recombinant TCRs. The patent provides a framework for further research and development in the field of immunotherapy and cancer treatment using genetically modified immune cells.
To know more about GlobalData’s detailed insights on Cellectis, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
